ASX-Listed Holista Colltech Reverses Six Years of Losses to Post

First Profit For FY2015; Prepares For Growth Via Patented Ovine
Collagen And Food Ingredients
Perth 28 August 2015 ASX-Listed Holista CollTech Ltd (Holista or the Group) said today it
has reversed six years of losses to post profit attributable to owners of A$33,488 for the financial
year ended 30 June 2015 ("FY2015") after completing major R&D milestones and recording higher
sales for new proprietary products.
The profit, against a loss of A$3.28 million in FY2014, was achieved despite non-cash foreign
exchange translation losses of A$22,759. This was largely due to the significant weakening of the
Malaysian ringgit (in which most current sales of Dietary Supplements are denominated) against
the Australian dollar, as well as costs incurred to commercialise the Group's food ingredients
business in the U.S. As the Group also purchases some raw materials from the U.S., it has also
been affected by the dramatic rise of the greenback.
The turnaround to profit was achieved on the back of 9% increase in turnover to A$6.79 million
from A$6.23 million, mainly from sales of Dietary Supplements in Malaysia and of Sheep Collagen.
For the last three years, revenue from Holistas proprietary cosmetic grade sheep collagen has
been increasing, with sales reaching a high of A$187,715 in FY2015.
As the consumption of sheep collagen is free of religious or cultural issues compared to pig and
cow sources and Australia is the only nation whose sheep are certified to be disease-free, the
Group believes that this product will continue to have significant growth potential.
The Group intends to launch food-grade sheep collagen in FY2016, which is expected to record
higher revenues compared to cosmetic collagen. The daily dose of food-grade collagen is 150
grams a month, which is 150 times greater than in cosmetic collagen, where only one gram is used.
It is targeting direct marketing companies, amongst other sales and distribution channels. Towards
this end, the Group intends to commission new equipment at its plant in Collie, Australia in the first
quarter of 2016.
While Malaysian sales of dietary supplements comprise the major revenue contributor, the Group
believes that future growth will come increasingly from a combination of overseas sales of
supplements, food-grade collagen, and its suite of four healthy food ingredients: Low Sodium Salt;
Low Calorie Sugar; Low Glycemic Index (GI); and Low Fat Chip.
Of these products, the Group has begun selling its Low Sodium Salt and Low Calorie Sugar, albeit
at a lower scale, in one of its Malaysian subsidiaries. As these ingredients target the Business to
Consumer (B2C) market, it will require substantial capital to promote. While there has been
encouraging demand for the products showing consumer interest and opportunity to expand the
Group believes the Business to Business (B2B) model is a more appropriate method with which to
launch the business.
Healthy food ingredients have gained overseas attention in the U.S., where the Group is working
with several fast food companies. The Group is also conducting final trials on its Low GI ingredient
with a potential European customer in the University of Sydney, with results expected in September

2015. Large-scale commercial testing of the Low Fat Chip will begin in Europe in the last quarter of
2016.
Commenting on Group-wide efforts to achieve financial turnaround, Holista CEO Dato Dr. Rajen
noted that the bulk of Holistas research and development was completed in FY2015, ending
almost six years of loss-making performance as the Group invested in research and development.
"The completion of most R&D activities comes at a time when we have established relationships
with international partners. As a result, we will soon be able to bring more of our key products to
market. These include sheep collagen, which I believe has significant potential as a new revenue
driver for the Group, as it is the only mammalian collagen on the market that is safe for
consumption without cultural or religious issues," he said.
"I wish to reiterate our commitment to adding value for our shareholders, and would like to thank
our shareholders and partners for their patience. Holista will step up its efforts to become a worldclass manufacturer of proprietary food ingredients," he added.
Going forward, the Group will establish global distribution rights for its biopharmaceutical products,
which the Group will expand as it moves up the value chain.

End of Press Release

About Holista CollTech Ltd (HCT)

Holista CollTech Ltd (Holista) is a research-driven biotech company and is the result of the
merger of Holista Biotech Sdn. Bhd. and CollTech Australia Ltd. Headquartered in Malaysia,
Holista is dedicated to delivering first-class natural ingredients and wellness products and leads in
research on herbs and food ingredients from Malaysias rainforest the oldest in the world.
Holista researches, develops, manufactures and markets health-style products to address the
unmet and growing needs of natural medicine. It is the only company to produce sheep (ovine)
collagen using patented extraction methods, and is on track in nano-nising and encapsulating
liposomes for the ovine collagen.
Holista aims to build a world-class company which provides consumers with scientifically
enhanced, engineered and tested natural health supplements and consumer products.
For more information on Holista: www.holistaco.com.
For further information, please contact us at:
Corporate Affairs & Business Opportunities
Dato Dr Rajen M: rajen.m@holistaco.com
General Enquiries: enquiries@holistaco.com

Australia
Level 18, Central Park
152-158 St Georges Terrace
Perth, WA 6000
P: +618-9278-2736; F: + 618-9288-1842
Malaysia
12th Floor, Amcorp Trade Centre, PJ Tower
No. 18, Persiaran Barat off Jalan Timur
46000 Petaling Jaya, Malaysia
P: +603 7965 2828; F: + 603 7965 277
Media and Investor Relations Enquiries:
WeR1 Consultants
Ms Sheryl Sim; sheryl@wer1.net
Ms Rachael De Foe; rachaeldefoe@wer1.net
P: + 65 6737 7488